AIMT - Aimmune Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Currency in USD

Valuation Measures

Premium required to access annual data
Annual
Quarterly
Premium required to access monthly data
Monthly
Subscribe to Premium to download historical data
We’re sorry, we weren’t able to find any data.
Please try reloading the page.

Trading Information

Stock Price History

Beta (5Y Monthly) 0.99
52-Week Change 3-13.98%
S&P500 52-Week Change 38.87%
52 Week High 337.00
52 Week Low 310.09
50-Day Moving Average 316.83
200-Day Moving Average 324.01

Share Statistics

Avg Vol (3 month) 31.45M
Avg Vol (10 day) 3856.51k
Shares Outstanding 565.25M
Float 42.75M
% Held by Insiders 120.86%
% Held by Institutions 182.85%
Shares Short (Apr 29, 2020) 417.62M
Short Ratio (Apr 29, 2020) 414.26
Short % of Float (Apr 29, 2020) 438.26%
Short % of Shares Outstanding (Apr 29, 2020) 427.02%
Shares Short (prior month Mar 30, 2020) 415.47M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2019
Most Recent Quarter (mrq)Mar 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-48,705.91%

Management Effectiveness

Return on Assets (ttm)-45.81%
Return on Equity (ttm)-114.24%

Income Statement

Revenue (ttm)575k
Revenue Per Share (ttm)0.01
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -275.34M
Net Income Avi to Common (ttm)-280.66M
Diluted EPS (ttm)-4.44
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)358.35M
Total Cash Per Share (mrq)5.49
Total Debt (mrq)140.45M
Total Debt/Equity (mrq)59.75
Current Ratio (mrq)8.10
Book Value Per Share (mrq)3.60

Cash Flow Statement

Operating Cash Flow (ttm)-221.39M
Levered Free Cash Flow (ttm)-139.87M